Centre selected in third round of last year’s NHL Draft looking to make a name for himself after father left his mark in ...

Olivia was diagnosed with stage four Hodgkin Lymphoma in 2023 and had to undergo aggressive chemotherapy. Since she is an avid gamer, the team set up a gaming system to distract her during infusions.

Media Contact: Kristen Ingram, (650) 467-6800 Advocacy Contact: Catherine Creme Henry, (202) 258-8228 Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, +41 61 687 5284 ...

The new Team of the Week prize is 96 overall Olli Jokinen while the HUT Champs rewards are 95 and 96 overall Saku Koivu for winning 10 games or finishing top 100 respectively.

FL represents roughly 20% to 30% of all non-Hodgkin lymphoma diagnoses, with approximately 14,000 new cases diagnosed in the US annually. | Image credit: wladimir1804 - stock.adobe.com ...

Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved ...

More information: Angie Mae Rodday et al, An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma, NEJM Evidence (2025). DOI: 10.1056/EVIDoa2500115 ...

CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...

Key Takeaways SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy ...

MCL is a rare, aggressive form of non-Hodgkin lymphoma. 4 The current standard of care in the frontline setting for young and fit patients is a chemotherapy regimen including ASCT, which can be ...

TRIANGLE (NCT02858258) is an ongoing, European, randomised, open-label, Phase 3 investigator initiated study (IIS) led by the European MCL Network. 2,3 It compared three treatment arms: ibrutinib ...

Lunsumio is already approved for people with R/R follicular lymphoma after two or more lines of therapy in more than 60 countries worldwide. Polivy in combination with MabThera/Rituxan, ...